Program
HT-102
A development code. Also written as “HT-101 + HT-102”.
Its studies are mostly in Hepatitis B, Chronic, led by Suzhou HepaThera Biotech.
Furthest: phase 2, since Nov 17, 20253 company-led studies, 2 open or runningNext primary completion: Feb 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Suzhou HepaThera Biotech | 32 open or running | phase 2since Nov 17, 2025 | Dec 9, 2024 | Feb 2027phase 2 · NCT07245953 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 9, 2024First study: phase 1 study in Hepatitis B, ChronicFirst studyNCT06744686 · 56 enrolled · China
- Nov 17, 2025Phase 2 study in Hepatitis B, ChronicPhase 2 reachedNCT07245953 · 60 enrolled · China
- Oct 29, 2026Phase 2 study in Hepatitis B, ChronicNCT07917910 · 120 planned
Ahead
- Feb 2027Primary completion: phase 2 study in Hepatitis B, ChronicNCT07245953
- Oct 30, 2028Primary completion: phase 2 study in Hepatitis B, ChronicNCT07917910
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07917910Hepatitis B, Chronic | 2 | Not yet recruiting | Oct 30, 2028 | 120 |
| NCT07245953Hepatitis B, Chronic · China | 2 | Active, not recruiting | Feb 2027 | 60 |
| NCT06744686Hepatitis B, Chronic · China | 1 | Completed | Mar 12, 2024 | 56 |
How it is read
Names in the registry
- “HT-102”, 3 entries
- “HT-101 + HT-102”, 1 entry
Codes read as this program: HT102.
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.